Journal of Renal Nutrition
Volume 16, Issue 2 , Pages 87-99 , April 2006

New Therapies for Uremic Secondary Hyperparathyroidism

  • Pablo Ureña Torres, MD

      Affiliations

    • Service de Néphrologie et Dialyse, Clinique de I’Orangerie, Aubervilliers, France
    • Service de Physiologie-Explorations Fonctionnelles, hôpital Necker, Paris, France
    • Corresponding Author InformationAddress reprint requests to Pablo Ureña Torres MD, Service de Néphrologie et Dialyse, Clinique de I’Orangerie, 11 boulevard Anatole France, 93300, Aubervilliers, France
    • ,
  • Dominique Prié, MD

      Affiliations

    • Service de Néphrologie et Dialyse, Clinique de I’Orangerie, Aubervilliers, France
    • ,
  • Laurent Beck, PhD

      Affiliations

    • Service de Néphrologie et Dialyse, Clinique de I’Orangerie, Aubervilliers, France
    • ,
  • Gérard Friedlander, MD

      Affiliations

    • Service de Néphrologie et Dialyse, Clinique de I’Orangerie, Aubervilliers, France

References 

  1. Young EW , Akiba T , Albert JM , et al.   Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS) . Am J Kidney Dis . 2004;44:34–38
  2. Slatopolsky E , Caglar S , Pennell JP , et al.   On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog . J Clin Invest . 1971;50:492–499
  3. London GM , Guerin AP , Marchais SJ , et al.   Arterial media calcification in end-stage renal disease (Impact on all-cause and cardiovascular mortality) . Nephrol Dial Transplant . 2003;18:1731–1740
  4. Massry SG , Smogorzewski M . Mechanisms through which parathyroid homone mediates its deleterious effects on organ function in uremia . Semin Nephrol . 1994;14:219–231
  5. Rostand SG , Drueke TB . Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure . Kidney Int . 1999;56:383–392
  6. Amann K , Ritz E . Cardiac disease in chronic uremia (Pathophysiology) . Adv Ren Replace Ther . 1997;4:212–224
  7. Amann K , Tornig J , Flechtenmacher C , et al.   Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia (Evidence for a permissive action of PTH) . Nephrol Dial Transplant . 1995;10:2043–2048
  8. Kosch M , Hausberg M , Vormbrock K , et al.   Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy . Cardiovasc Res . 2000;47:813–818
  9. Ganesh SK , Stack AG , Levin NW , et al.   Association of elevated serum PO4, Ca PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients . J Am Soc Nephrol . 2001;12:2131–2138
  10. Foundation NK . K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease . Am J Kidney Dis . 2003;42:S1–S202
  11. Gagné ER , Ureña P , Leite-Silva S , et al.   Short and long-term efficacity of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients . J Am Soc Nephrol . 1992;3:1008–1017
  12. Cunningham J , Makin H . How important is vitamin D deficiency in uraemia? . Nephrol Dial Transplant . 1997;12:16–18
  13. Eastwood JB , Harris E , Stamp TCB , et al.   Vitamin-D deficiency in the osteomalacia of chronic renal failure . Lancet . 1976;1:1209–1211
  14. Ghazali A , Fardellone P , Pruna A , et al.   Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser’s zones independent of calcitriol? . Kidney Int . 1999;55:2169–2177
  15. LaClair RE , Hellman RN , Karp SL , et al.   Prevalence of calcidiol deficiency in CKD (A cross-sectional study across latitudes in the United States) . Am J Kidney Dis . 2005;45:1026–1033
  16. Brown AJ , Zhong M , Finch J , et al.   The role of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands . Endocrinology . 1995;136:1419–1425
  17. Patel SR , Ke HQ , Hsu CH . Regulation of calcitriol receptor and its mRNA in normal and renal failure rats . Kidney Int . 1994;1994:1020–1027
  18. Stevens LA , Djurdjev O , Cardew S , et al.   Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality (Evidence for the complexity of the association between mineral metabolism and outcomes) . J Am Soc Nephrol . 2004;15:770–779
  19. Teng M , Wolf M , Ofsthun MN , et al.   Activated injectable vitamin D and hemodialysis survival (A historical cohort study) . J Am Soc Nephrol . 2005;16:1115–1125
  20. Drueke TB . Control of secondary hyperparathyroidism by vitamin D derivatives . Am J Kidney Dis . 2001;37:S58–S61
  21. Kubrusly M , Gagne ER , Urena P , et al.   Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism . Kidney Int . 1993;44:551–556
  22. Silver J , Kilav R , Naveh-Many T . Mechanisms of secondary hyperparathyroidism . Am J Physiol Renal Physiol . 2002;283:F367–F376
  23. Felsenfeld AJ . Considerations for the treatment of secondary hyperparathyroidism in renal failure . J Am Soc Nephrol . 1997;8:993–1004
  24. Llach F . Hyperphosphatemia in end-stage renal disease patients (Pathophysiological consequences) . Kidney Int Suppl . 1999;73:S31–S37
  25. Aparicio M , Combe C , Lafage MH , et al.   In advanced renal failure, dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the levels of calcitriol . Nephron . 1993;63:122–123
  26. Chertow GM , Martin KJ . Current and future therapies for the medical management of secondary hyperparathyroidism . Sem Dial . 1998;11:267–270
  27. vandenBergh JP , Gelens MA , Klaassen HA , et al.   Efficacy and tolerance of three different calcium acetate formulations in hemodialysis patients . Neth J Med . 1999;55:222–228
  28. Hutchison AJ , Maes B , Vanwalleghem J , et al.   Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia (A 6-month, randomized, comparative trial versus calcium carbonate) . Nephron Clin Pract . 2005;100:c8–c19
  29. Litzow JR , Lemann J , Lennon EJ . The effect of treatment of acidosis on calcium balance in patients with chronic azotemic renal disease . J Clin Invest . 1967;46:280–286
  30. Green J , Maor G . Effect of metabolic acidosis on the growth hormone/IGF-I endocrine axis in skeletal growth centers . Kidney Int . 2000;57:2258–2267
  31. McSherry E , Morris RC . Attainment and maintenance of normal stature with alkali therapy in infants and children with classic renal tubular acidosis . J Clin Invest . 1978;61:509–527
  32. Lefebvre A , deVernejoul MC , Gueris J , et al.   Optimal correction of acidosis changes progression of dialysis osteodystrophy . Kidney Int . 1989;36:1112–1118
  33. Sudhaker Rao D , Han ZH , Phillips ER , et al.   Reduced vitamin D receptor expression in parathyroid adenomas (Implications for pathogenesis) . Clin Endocrinol (Oxf) . 2000;53:373–381
  34. Li YC , Pirro AE , Amling M , et al.   Targeted ablation of the vitamin D receptor (An animal model of vitamin D-dependent rickets type II with alopecia) . Proc Natl Acad Sci U S A . 1997;94:9831–9835
  35. Li YC , Amling M , Pirro AE , et al.   Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice . Endocrinology . 1998;139:4391–4396
  36. Goltzman D , Miao D , Panda DK , et al.   Effects of calcium and of the Vitamin D system on skeletal and calcium homeostasis (Lessons from genetic models) . J Steroid Biochem Mol Biol . 2004;89-90:485–489
  37. Panda DK , AI Kawas S , Seldin MF , et al.   25-hydroxyvitamin D 1 alpha-hydroxylase (Structure of the mouse gene, chromosomal assignment, and developmental expression) . J Bone Miner Res . 2001;16:46–56
  38. Gogusev J , Duchambon P , Hory B , et al.   Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism . Kidney Int . 1997;51:328–336
  39. Brown AJ , Zhong M , Finch J , et al.   Rat calcium-sensing receptor is regulated by vitamin D but not by calcium . Am J Physiol . 1996;270:F454–F460
  40. Rodica E , Adler G , Kifor O , et al.   Calcium-sensing receptor expression and regulation by extracellular calcium in the AtT-20 pituitary cell line . Mol Endocrinol . 1996;10:555–565
  41. Yarden N , Lavelin I , Genina O , et al.   Expression of calcium-sensing receptor gene by avian parathyroid gland in vivo (Relationship to plasma calcium) . Gen Comp Endocrinol . 2000;117:173–181
  42. Brown EM . Physiology and pathophysiology of the extracellular calcium-sensing receptor . Am J Med . 1999;106:238–253
  43. Mizobuchi M , Hatamura I , Ogata H , et al.   Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency . J Am Soc Nephrol . 2004;15:2579–2587
  44. Autry C , Kifor O , Brown E , et al.   Ca2+ receptor mRNA and protein increase in the rat parathryoid gland with advancing age . J Endocrinol . 1997;153:437–444
  45. Nielsen PK , Rasmussen AK , Butters R , et al.   Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium- sensing receptor mRNA . Biochem Biophys Res Commun . 1997;238:880–885
  46. Brown EM , Brennan MF , Hurwitz S , et al.   Dispersed cells prepared from human parathyroid glands (Distinct calcium sensitivity of adenomas vs. primary hyperplasia) . J Clin Endocrinol Metab . 1978;46:267–275
  47. Brown EM , Gardner DG , Brennan MF , et al.   Calcium-regulated parathyroid hormone release in primary hyperparathyroidism (studies in vitro with dispersed parathyroid cells) . Am J Med . 1979;66:923–931
  48. Brown EM , Rown EM , Wilson RE , et al.   Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure . J Clin Endocrinol Metab . 1982;54:172–179
  49. Habener JF . Responsiveness of neoplastic and hyperplastic parathyroid tissue to calcium in vitro . J Clin Invest . 1978;62:436
  50. Caligara F , Giagrande A , Allaria P , et al.   The PTH-calcium relationship curve in secondary hyperparathyroidism, an index of sensitivity and suppressibility of parathyroid glands . Nephrol Dial Transplant . 1996;11:136–141
  51. Cardinal H , Brossard JH , Roy L , et al.   The set point of parathyroid hormone stimulation by calcium is normal in progressive renal failure . J Clin Endocrinol Metab . 1998;83:3839–3844
  52. Messa P , Vallone C , Mioni G , et al.   Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients . Kidney Int . 1994;46:1713–1720
  53. Pahl M , Jara A , Bover J , et al.   The set point of calcium and the reduction of parathyroid hormone in hemodialysis patients . Kidney Int . 1996;49:226–231
  54. Ramirez JA , Goodman WG , Gornbein J , et al.   Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism . J Clin Endocrinol Metab . 1993;76:1489–1494
  55. Ramirez JA , Goodman WG , Belin TR , et al.   Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism . Am J Physiol . 1994;267:E961–E967
  56. Schindler S , Mannstadt M , Urena P , et al.   PTH secretion in patients with chronic renal failure assessed by a modified CiCa clamp method (Effects of 1- year calcitriol therapy) . Clin Nephrol . 2004;61:253–260
  57. Delmez JA , Tindira C , Grooms P , et al.   Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium . J Clin Invest . 1989;83:1349–1355
  58. Dunlay R , Rodriguez M , Felsenfeld AJ , et al.   Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis . Kidney Int . 1989;36:1093–1098
  59. Bas S , Aguilera-Tejero E , Bas A , et al.   The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve . J Endocrinol . 2005;184:241–247
  60. Rodriguez M , Caravaca F , Fernandez E , et al.   Evidence for both abnormal set point of PTH stimulation by calcium and adaptation to serum calcium in hemodialysis patients with hyperparathyroidism . J Bone Miner Res . 1997;12:347–355
  61. Nemeth EF , Steffey ME , Hammerland LG , et al.   Calcimimetics with potent and selective activity on the parathyroid calcium receptor . Proc Natl Acad Sci U S A . 1998;95:4040–4045
  62. Hammerland L , Garrett J , Hung B , et al.   Allosteric activation of the Ca2+ receptor in xenopus laevis oocytes by NPS 467 or NPS 568 . Mol Pharmacol . 1998;53:1083–1088
  63. Block GA , Martin KJ , deFrancisco AL , et al.   Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis . N, Engl J Med . 2004;350:1516–1525
  64. Coburn J , Barri Y , Turner S , et al.   Single doses of the calcimimetic AMG-073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism . J Am Soc Nephrol . 2000;11:573A
  65. Ureña P , Basile C , Grateau G , et al.   Short-term effects of parathyroidectomy on plasma biochemistry in chronic uremia (A prospective study) . Kidney Int . 1989;36:120–126
  66. Van Abel M , Hoederop JGJ , Van Leeuwen JPTM . Down-regulation of Ca2+ transporters in kidney and duodenum by the calcimimetic compound NPS R-467 . J Am Soc Nephrol . 2003;14:SA-P073; (abstr)
  67. Drueke T , Cunningham J , Goodman W , et al.   Short-term treatment of secondary hyperparathyroidism (SHTP) with the calcimimetic agent AMG 073 . J Am Soc Nephrol . 2001;12:764A
  68. Urena P , Legoupil N , de Vernejoul MC , et al.   Sustained control of uraemic secondary hyperparathyroidism (SHPT) after three years of treatment with the calcimimetic Cinacalcet HCL (A single centre experience) . 2003; Poster presented at the 40th ERA-EDTA World Congress of Nephrology, Berlin
  69. Quarles LD , Sherrard DJ , Adler S , et al.   The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease . J Am Soc Nephrol . 2003;14:575–583
  70. Lindberg JS , Moe SM , Goodman WG , et al.   The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism . Kidney Int . 2003;63:248–254
  71. Mittman N , Finkelstein F , Culleton B , et al.   Cinacalcet HCL (Sensipar) for the management of secondary hyperparathyroidism in study patients receiving peritoneal dialysis . J Am Soc Nephrol . 2004;15:280A
  72. Bushinsky DA . Cinacalcet HCL in secondary hyperparathyroidism. Official Evening Symposium of the American Society of Nephrology (ASN) . 2004; St. Louis, MO, October 28–November 1
  73. Moe SM , Chertow GM , Coburn JW , et al.   Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCL . Kidney Int . 2005;67:760–771
  74. Moe SM , Sprague SM , Cunningham J , et al.   Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCL . Nephrol Dial Transplant . 2005;20:2186–2193
  75. Cunningham J , Danese M , Olson K , et al.   Effects of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture and health-related quality of life in secondary hyperparathyroidism . Kidney Int . 2005;68:1793–1800
  76. Evenepoel P , Claes K , Kuypers D , et al.   Natural history of parathyroid function and calcium metabolism after kidney transplantation (A single-centre study) . Nephrol Dial Transplant . 2004;19:1281–1287
  77. Kruse AE , Eisenberger U , Frey FJ , et al.   The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism . Nephrol Dial Transplant . 2005;20:1311–1314
  78. Serra AL , Schwarz AA , Wick FH , et al.   Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism . Nephrol Dial Transplant . 2005;20:1315–1319
  79. Silverberg SJ , Bone HG , Marriott TB , et al.   Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism . N Engl J Med . 1997;337:1506–1510
  80. Rubin MR , Sliney J , Silverberg SJ , et al.   Clinical course of 10 patients with inoperable parathyroid carcinoma treated with the calcimimetic cinacalcet HCL . J Bone Miner Res . 2004;F497; (abstr)
  81. Kifor O , McElduff A , Leboff MS , et al.   Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism . J Clin Endocrinol Metab . 2004;89:548–556
  82. Kifor O , Moore F , Wang P , et al.   Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism . J Clin Endocrinol Metab . 1996;81:1598–1606
  83. Pallais JC , Kifor O , Chen YB , et al.   Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor . N Engl J Med . 2004;351:362–369
  84. Hindie E , Urena P , Jeanguillaume C , et al.   Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism . Lancet . 1999;353:2200–2204
  85. Jeanguillaume C , Urena P , Hindie E , et al.   Secondary hyperparathyroidism (Detection with I–123-Tc-99m-sestamibi subtraction scintigraphy versus US) . Radiology . 1998;207:207–213
  86. Tanaka Y , Seo H , Tominaga Y , et al.   Factors related to the recurrent hyperfunction of autografts after total parathyroidectomy in patients with severe secondary hyperparathyroidism . Surg Today . 1993;23:220–227
  87. Tominaga Y , Katayama A , Sato T , et al.   Re-operation is frequently required when parathyroid glands remain after initial parathyroidectomy for advanced secondary hyperparathyroidism in uraemic patients . Nephrol Dial Transplant . 2003;18(suppl 3):65–70 iii
  88. Hindie E , Melliere D , Jeanguillaume C , et al.   Unilateral surgery for primary hyperparathyroidism on the basis of technetium Tc 99m sestamibi and iodine 123 subtraction scanning . Arch Surg . 2000;135:1461–1468
  89. Miccoli P . Parathyroid surgery (We only need a minimal surgical approach) . J Endocrinol Invest . 2005;28:570–573
  90. Fukagawa M , Kitaoka M , Tominaga Y , et al.   Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients . Nephrol Dial Transplant . 2003;18(suppl 3):31–33 iii
  91. Shiizaki K , Hatamura I , Negi S , et al.   Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia . Kidney Int . 2003;64:992–1003
  92. Shiizaki K , Negi S , Hatamura I , et al.   Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats . J Am Soc Nephrol . 2005;16:97–108
  93. Shiizaki K , Negi S , Mizobuchi M , et al.   Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients . Nephrol Dial Transplant . 2003;18(suppl 3):42–46 iii
  94. Cozzolino M , Lu Y , Finch J , et al.   p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium . Kidney Int . 2001;60:2109–2117
  95. Cozzolino M , Lu Y , Sato T , et al.   A critical role for enhanced-TGF α and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease . Am J Physiol Renal Physiol . 2005;289:F1096–F1102
  96. Izuta S , Saneyoshi M , Sakurai T , et al.   The 5′-triphosphates of 3′-azido-3′-deoxythymidine and 2′, 3′-dideoxynucleosides inhibit DNA polymerase gamma by different mechanisms . Biochem Biophys Res Commun . 1991;179:776–783
  97. Falchetti A , Franchi A , Bordi C , et al.   Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture . J Bone Miner Res . 2005;20:410–418
  98. Bell O , Gaberman E , Kilav R , et al.   The protein phosphatase calcineurin determines basal parathyroid hormone gene expression . Mol Endocrinol . 2005;19:516–526
  99. D’Amour P , Brossard JH , Rousseau L , et al.   Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism . Kidney Int . 2005;68:998–1007
  100. Divieti P , Geller AI , Suliman G , et al.   Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells (Determinants of ligand binding and bioactivity) . Endocrinology . 2005;146:1863–1870
  101. Divieti P , John MR , Juppner H , et al.   Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor . Endocrinology . 2002;143:171–176
  102. Murray TM , Rao LG , Divieti P , et al.   Parathyroid hormone secretion and action (Evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands) . Endocr Rev . 2005;26:78–113
  103. Slatopolsky E , Finch J , Clay P , et al.   A novel mechanism for skeletal resistance in uremia . Kidney Int . 2000;58:753–761
  104. Kihara T , Ichikawa H , Morimoto H , et al.   Intravenous vitamin D therapy reduces PTH-(1-84)/large C fragments ratio in chronic hemodialysis patients . Nephron Clin Pract . 2004;98:c93–c100
  105. Pollock AS , Shoback DM , Arends RH , et al.   Treatment of severe hyperparathyroidism secondary to parathyroid cancer with ABX10241, a fully human monoclonal antibody directed against parathyroid hormone . J Am Soc Nephrol . 2004;15:279A
  106. Sahni M , Guenther HL , Fleisch H , et al.   Bisphosphonates act on bone resorption through the mediation of osteoblasts . J Clin Invest . 1993;91:2004–2011
  107. Inzerillo AM , Zaidi M , Huang CL . Calcitonin (The other thyroid hormone) . Thyroid . 2002;12:791–798
  108. Coburn JW , Brickman AS , Massry SG . Medical treatment in primary and secondary hyperparathyroidism . Semin Drug Treat . 1972;2:117–135
  109. Ishida M , Yamada M . [Calcitonin for therapy of renal osteodystrophy due to long- term hemodialysis in patients with chronic kidney failure] . Nippon Rinsho . 1991;49(suppl):725–731
  110. Matuszkiewicz-Rowinska J , Niemczyk S , Przedlacki J , et al.   [Effect of salmon calcitonin on bone mineral density and calcium- phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism] . Pol Arch Med Wewn . 2004;112:797–803
  111. Matuszkiewicz-Rowinska J , Niemczyk S , Puka J , et al.   [Combined therapy with calcitonin and high doses of active vitamin D3 metabolites in uremic hyperparathyroidism] . Pol Arch Med Wewn . 1996;96:23–31
  112. Simonet WS , Lacey DL , Dunstan CR , et al.   Osteoprotegerin (A novel secreted protein involved in the regulation of bone density) . Cell . 1997;89:309–319
  113. Avbersek-Luznik I , Malesic I , Rus I , et al.   Increased levels of osteoprotegerin in hemodialysis patients . Clin Chem Lab Med . 2002;40:1019–1023
  114. Kazama JJ . Osteoprotegerin and bone mineral metabolism in renal failure . Curr Opin Nephrol Hypertens . 2004;13:411–415
  115. Nitta K , Akiba T , Uchida K , et al.   The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis . Am J Kidney Dis . 2003;42:303–309
  116. Cundy T , Davidson J , Rutland MD , et al.   Recombinant osteoprotegerin for juvenil Paget’s disease . N Engl J Med . 2005;353:918–923
  117. Usdin TB , Gruber C , Bonner TI . Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor . J Biol Chem . 1995;270:15455–15458

PII: S1051-2276(06)00011-2

doi: 10.1053/j.jrn.2006.01.011

Journal of Renal Nutrition
Volume 16, Issue 2 , Pages 87-99 , April 2006

Article Tools